Search
Otilimab
go.drugbank.com/drugs/DB06303InvestigationalInvestigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).
BGB-DXP593
go.drugbank.com/drugs/DB16357Investigational[L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants
Tasurgratinib
go.drugbank.com/drugs/DB21222InvestigationalThe usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor. … Tasurgratinib is under investigation in clinical trial NCT04962867 (NCCH2006/MK010 Trial (FORTUNE Trial)). Tasurgratinib has a monoisotopic molecular weight of 587.27 Da.
Synonyms: E 7090Sifalimumab
go.drugbank.com/drugs/DB12773InvestigationalSifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients. … The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity.
Ganulameran
go.drugbank.com/drugs/DB16442InvestigationalAs such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.